-
Mashup Score: 13Distinct Hodgkin lymphoma subtypes defined by noninvasive genomic profiling - Nature - 3 month(s) ago
The potential use of circulating tumour DNA in classic Hodgkin lymphoma detection, classification and monitoring is defined.
Source: www.nature.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 2Underrepresented Minority Medical Student Research Program | Leukemia and Lymphoma Society - 6 month(s) ago
Underrepresented Minority Medical Student Research Program > Page Components
Source: www.lls.orgCategories: General Medicine News, Onc News and JournalsTweet-
This program is now open and ready to accept applications from talented & ambitious med students who are ready to spend a year in a prestigious blood cancer research lab and fall in ♥️ with the specialty. #MedTwitter please help spread this opportunity 👉https://t.co/R4PNLuhp4Y https://t.co/igPiLgG4Vb
-
-
Mashup Score: 3LinkedIn - 8 month(s) ago
This link will take you to a page that’s not on LinkedIn
Source: lnkd.inCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
It's open season on blood cancer at @LLSusa! We have career development grants, translational, clinical and discovery science funding opportunities! To learn more, go to https://t.co/SgBz9npxfM Please share with your followers. https://t.co/gPT3vzwCeB
-
-
Mashup Score: 2
Apply to the Career Development Program (CDP) > Page Components
Source: www.lls.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Since 1992, the Career Development Program #LLSCDP has been providing support to promising early-career scientists. The 2023-2024 application cycle is open right now!! 👉https://t.co/95Qk834FXn Please share! https://t.co/R4m653xTne
-
-
Mashup Score: 0Prediction and prevention of therapy-related myeloid neoplasms following autologous transplantation | Leukemia and Lymphoma Society - 1 year(s) ago
The proposed studies will identify alterations in hematopoietic regulation that predict for risk for therapy-related myeloid neoplasm (TMN) and improve understanding of disease evolution to guide strategies to prevent TMN in patients receiving autologous hematopoietic cell transplantation (aHCT) for lymphoma. They will investigate alterations in hematopoietic function in peripheral blood stem…
Source: www.lls.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
The LLS grantee of the month is @RaviBha65448036 Read about his #llsTRP project: 👉https://t.co/9Go48xOxH9 https://t.co/bbBpo0pubg
-
-
Mashup Score: 4Navigating the Frontier of Hematologic Malignancy Therapies - 1 year(s) ago
This activity will cover the latest advances in the therapeutic management of hematologic malignancies, including bispecific antibodies, CAR-T products, proteolysis-targeting chimeras, and antibody-drug conjugates — with an emphasis on novel targets and approaches. The prognostic role of…
Source: freeCME.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Did you miss our #ASH22 Symposium "Navigating the Frontier of Hematologic Malignancy Therapies"? Hear from experts & earn CME credits: @szusmani, @RoschewskiMD and Drs. Katherine Donovan @DanaFarber, Soheil Meshinchi @fredhutch & Helen Heslop @bcmhouston 👉https://t.co/WJ6EkN8tDv https://t.co/PBfcDy0Czp
-
-
Mashup Score: 0Prediction and prevention of therapy-related myeloid neoplasms following autologous transplantation | Leukemia and Lymphoma Society - 1 year(s) ago
The proposed studies will identify alterations in hematopoietic regulation that predict for risk for therapy-related myeloid neoplasm (TMN) and improve understanding of disease evolution to guide strategies to prevent TMN in patients receiving autologous hematopoietic cell transplantation (aHCT) for lymphoma. They will investigate alterations in hematopoietic function in peripheral blood stem…
Source: www.lls.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Let's all celebrate @RaviBha65448036 who is now the John G. Kelton, M.D., Endowed Chair in Hematology and Oncology at @uabmedicine @UABDeptMed 👏 Dr. Bhatia is a TRP grantee, a cherished friend of #LLSResearch and a sworn enemy of leukemia. 👉https://t.co/9Go48xOxH9 https://t.co/C3gZuj3cl1
-
-
Mashup Score: 3Project Finder | Leukemia and Lymphoma Society - 1 year(s) ago
Christopher Booth, PhD Dana-Farber Cancer Institute Boston, Massachusetts United States Mechanisms of Pathogenesis by MYB Fusions in Blastic Plasmacytoid Dendritic Cell Neoplasm The transcription factor MYB has long been associated with leukemia, but how it contributes to disease is poorly understood. Fusions of MYB to other proteins, causing MYB activation, are found in patients with…
Source: www.lls.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
🧵1/3 Today is World #BPDCN day. It is an incredibly rare indication but @LLSusa is deeply committed to all these patients through many years of supporting life saving research. For current #BPDCN projects see 👉https://t.co/Z4wytJJViL https://t.co/TKd9VDbg0x
-
-
Mashup Score: 2
Former TAP Partner SL-401 (Elzonris®, Tagraxofusp-erzs) is a CD123-directed cytotoxin first approved by the U.S. Food and Drug Administration on December 21 2018 and by the European Commission in January 2021. Elzonris®…
Source: www.lls.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
@LLSusa 🧵2/3 Elzonris is the 1st FDA approved therapy for children + adults with #BPDCN. 1st created with #LLSgrant support to Dr. Arthur Frankel @utsw. #LLSTAP committed $3M+ in a partnership w/ @Stemline supporting the clinical study leading to approval https://t.co/mSjSkeCasB
-
-
Mashup Score: 0
Strategic Venture Philanthropy Funding Initiative Since 2007 Apply Today LLS TAP: European Partners Dream Big, Make Bold Progress virtual discussion panel – Wednesday January 18 at 12pm EST Click to Register …
Source: www.lls.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Congrats to @BioInvent for becoming the latest #LLSTAP partner! We look forward to working closely together to help advance two clinical therapies for blood cancer patients! Visit our site to learn more about #LLSTAP and all of our portfolio partners: https://t.co/VVEzx2mWV0 https://t.co/Z8El0xLpWz
-
LLS-supported scientist @AshAlizadeh @StanfordMed publishes high impact paper in @Nature Circulating tumor DNA predicts disease recurrence & identifies Hodgkin subgroups with distinct genetic changes opening the door to potential future targeted treatments https://t.co/UAy3ApLfyt